Innate Pharma vs X4 Pharmaceuticals
IPHA and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IPHA and XFOR compare
X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus −55.2% for Innate Pharma).
X4 Pharmaceuticals scores higher on the StockData Score (3 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IPHA | XFOR |
|---|---|---|
| Size and price | ||
| Market cap | – | $320M |
| Share price | $1.59 | $3.23 |
| Change, 1 year | −30.9% | −11.0% |
| Change, 5 years | −68.3% | −97.7% |
| Beta (5Y) | 0.95 | 1.42 |
| Employees | 181 | 45 |
| StockData Score | ||
| Total score | 0 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 32.3× |
| P/B | – | 2.3× |
| Growth | ||
| Revenue growth (TTM) | −55.2% | 73.7% (better) |
| Revenue growth, 5Y average | −33.6% | 16.7% (better) |
| Profitability | ||
| Gross margin | – | 68.8% |
| Operating margin | −600% (better) | −812% |
| Net margin | – | −813% |
| FCF margin | −587% | – |
| Return on equity | – | −80.3% |
| Financial health | ||
| Interest coverage | −17.3× | −9.3× (better) |
| Current ratio | 0.60 | 13.22 (better) |
| Altman Z-score | – | −2.02 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.21% | 103% |
| Held by insiders | 16.2% | 12.2% |
| Insider net buying, 12 months | – | −$451K |
| Short interest, % of float | – | 9.2% |
Go deeper
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
- XFOR stock overview
- XFOR income statement
- XFOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.